The healthcare sector continued to be a hub of private equity (PE) deal activity in 2023, reaching $60 billion in announced deal value, despite higher global interest rates, inflationary pressures, and broader geopolitical uncertainty, Bain & Company said Wednesday. The consulting firm said in its 13th annual Global Healthcare Private Equity report that biopharma captured the bulk of dealmaking momentum, attributing for 48 percent of global deal value, including six deals in excess of $2 billion. The findings also showed that in 2024, investors will continue to bet on the transformative nature of generative artificial intelligence (AI); new modalities and innovative therapies, such as glucagon-like peptide-1 agonists (GLP-1s); and India as a place to deploy healthcare capital at scale. 'Innovation and technology will continue to be at the forefront of investment themes across the value chain. Investors should carefully consider the evolving role of AI, the impacts of GLP-1, and the...
learn more
